Filing Details
Calidi Biotherapeutics, Inc. (AMEX:CLDI) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event.
8k filedAMEX:CLDI
Calidi Biotherapeutics, Inc. (CLDI) Reports Material Event to SEC
Filing Details Calidi Biotherapeutics, Inc. (AMEX:CLDI) filed a Form 8-K with the Securities and Exchange Commission on July 16, 2026, disclosing a material event. Market Context…
Market Context
Calidi Biotherapeutics, Inc.'s stock currently trades at $0.12 with a market capitalization of $10.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Calidi Biotherapeutics, Inc.'s stock.
All SEC filings for Calidi Biotherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CLDI Stock Page
Frequently Asked Questions
Where can I read CLDI's SEC filings?
Browse all filings on our CLDI SEC filings page.
What types of SEC filings does Calidi Biotherapeutics, Inc. file?
Public companies like Calidi Biotherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.